Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1359-1368

  McInerney, Tracey L ^a   Brennan, Frank R ^b   Jones, Tim D ^b   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Axis Genetics plc   (United Kingdom)

Author keywords

Adjuvant; Antibody; Cowpea mosaic virus; HIV 1 gp41; Mouse; Neutralization; T cell; T helper cell response

Indexed keywords

ADJUPRIME; ALUMINUM POTASSIUM SULFATE; FREUND ADJUVANT; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; QUIL A; RIBI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; LYMPHOCYTE PROLIFERATION; MOSAIC VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS HYBRID; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CELL WALL SKELETON; CHIMERA; COMOVIRUS; CORD FACTORS; FREUND'S ADJUVANT; HIV ENVELOPE PROTEIN GP41; IMMUNIZATION, SECONDARY; LIPID A; MICE; RECOMBINANT FUSION PROTEINS; SAPONINS; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 0033577298     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00388-0     Document Type: Article

References (39)

1. Grun J.L., Maurer P.H. Different T-helper cell subsets elicited in mice utilizing 2 different adjuvant vehicles: the role of endogenous interleukin-1 proliferative responses. Cell. Immunol. 121:1989;134.
2. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145.
3. Coffman R.L., Varkila K., Scott P., Chatelain R. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol. Rev. 123:1991;189.
4. Powrie F., Coffman R.L. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol. Today. 14:1993;270.
5. Hussell T., Spender L.C., Georgiou A., O'Garra A., Openshaw P.J.M. Th1 and Th2 cytokine induction in pulmonary cells during infection with respiratory syncytial virus. J. Gen. Virol. 77:1996;2447.
6. Powell M.F., Eastman D.J., Lim A.et al. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res. Human Retrovir. 11:1995;203.
7. Berman P.W., Gregory T.J., Riddle L.et al. Protection of chimpanzees from infection by HIV-1 after vaccination with gp120 but not gp160. Nature (London). 345:1990;622.
8. Hart M.K., Palker T.J., Mathews T.J.et al. Synthetic peptides containing T- and B-cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titres of neutralizing antibodies in rhesus monkeys. J. Immunol. 145:1990;2677.
9. Schirmbeck R., Melber K., Mertens T., Reiman J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68:1994;1418.
10. O'Hagan D.T., Ott G.S., Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Molec. Med. Today. 3:1997;69.
11. Newman M.J., Wu J.-Y., Gardner B.H.et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T-lymphocyte responses. J. Immunol. 148:1992;2357.
12. Bomford R., Stapleton M., Winsor S., McKnight A., Andronova T. The control of the antibody isotype response to HIV gp120 by adjuvants. AIDS Res. Human Retrovir. 8:1992;1765.
13. Cox J.C., Coulter A.R. Adjuvants: a classification and review of their modes of action. Vaccine. 15:1997;248.
14. Kensil C.R. Saponins as vaccine adjuvants. Crit. Prev. Ther. Drug Carrier Syst. 13:1996;1.
15. Jiang W., Swiggard W.J., Heufler C.et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature (London). 375:1995;151.
16. Tsujimoto M., Kotani S., Okunaga T.et al. Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acyl muramyl-dipeptide and synthetic low toxicity analogues of lipid A. Vaccine. 7:1989;39.
17. Fries L.F., Gordon D.M., Richards R.L.et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA. 89:1992;352.
18. Ulrich JT, Ulrich KR. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. In: Powell M, Newman M, editors. Vaccine design: the subunit and adjuvant approach. Plenum, 1995. p. 495.
19. Takayama K., Olsen M., Datta P., Hunter R.I. Adjuvant activity of nonionic block copolymers. 5. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine. 9:1991;257.
20. Tomai M.A., Johnson A.G. T-cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J. Biol. Resp. Med. 8:1989;625.
21. McLain L., Porta C., Lomonossoff G.P., Durrani Z., Dimmock N.J. Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res. Human Retrovir. 11:1995;327.
22. McLain L., Durrani Z., Wisniewski L.A., Porta C., Lomonossoff G.P., Dimmock N.J. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine. 14:1996;799.
23. Dalsgaard K., Uttenthal A., Jones T.D.et al. Plant-derived vaccine protects target animals against a viral disease. Nature Biotech. 15:1997;248.
24. McLain L., Dimmock N.J. Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75:1994;1457.
25. Brusic V., Rudy G., Harrison L. MHCPEP: a database of MHC-binding peptides. Nucl. Acids Res. 22:1994;3663.
26. Wu J.-Y., Gardner B.H., Murphy C.I.et al. Saponin adjuvant enhancement of antigen-specific responses to an experiemntal HIV-1 vaccine. J. Immunol. 148:1992;1519.
27. O'Hagan D.T., McGee J.P., Boyle R.et al. The preparation, characterization and pre-clinical evaluation of an orally administered HIV-1 vaccine, consisting of a branched synthetic peptide immunogen entrapped in controlled release microparticles. J. Cont. Rel. 36:1995;75.
28. Cleland J.L., Powell M.F., Lim A.et al. Development of a single-shot subunit vaccine for HIV-1. AIDS Res. Human Retrovir. 10:1994;S21.
29. Porta C., Spall V.E., Loveland J., Johnson J.E., Barker P.J., Lomonossoff G.P. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology. 202:1994;949.
30. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol. Today. 16:1995;374.
31. Nerome K., Yoshioka Y., Ishida M.et al. Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses. Vaccine. 8:1990;503.
32. Byars N.E., Allison A.C., Harmon M.W., Kendal A.P. Enhancement of antibody responses to influenza haemagglutinin by use of a new adjuvant formulation. Vaccine. 8:1990;49.
33. Coutelier J.-P., van der Logt J.T.M., Heessen F.W.A., Warnier G., van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165:1987;64.
34. Rosenberg Y.J., Chiller J.M. Ability of antigen-specific helper cells to effect a class-restricted increase in total Ig-secreting cells in spleens after immunization with the antigen. J. Exp. Med. 150:1979;517.
35. Moreno C., Esdaile J. Immunoglobulin isotype in the murine response to polysaccharide antigens. Eur. J. Immunol. 13:1983;262.
36. Coutelier J.-P., Jos T.M., van der Logt J.T.M., Heessen F.W.A., Vink A., van Snick J. Virally induced modulation of murine IgG subclasses. J. Exp. Med. 168:1988;2373.
37. Vella C., Ferguson M., Dunn G.et al. Characterization and primary structure of a HIV-1 neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J. Gen. Virol. 74:1993;2603.
38. Buratti E, McLain L, Tisminetzky SG, Cleveland SM, Dimmock NJ, Baralle, FE. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J. Gen. Virol. 1998;79, 2709.
39. Gallaher W.R., Ball J.M., Garry R.F., Griffin M.C., Montelaro R.C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Human Retrovir. 5:1989;431.